Leprosy Susceptibility To 6 C3150676
Genetic variation that may raise the risk of acquiring leprosy, a bacterial disease affecting skin, nerves, and respiratory tract.
Key facts at a glance
- ICD-10
- R69
- ICD-11
- MA00.0
- Body system
- immunologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(immunologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Hypopigmented macules
(integumentary)Motor weakness in distal muscles
(neurologic)Progressive facial paralysis
(neurologic)Secondary amyloidosis
(immunologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Periodic nerve function assessment
Regular neurological examinations to detect early signs of peripheral nerve involvement, a hallmark of leprosy progression.
Avoidance of known leprosy risk factors
Minimizing prolonged close contact with untreated patients and improving living conditions in endemic areas when unavoidable.
Additional treatment options
Immunonutrition protocol
Dietary enrichment with omega-3 fatty acids, antioxidants, and trace minerals to support T-cell mediated immunity against intracellular pathogens.
dietaryHealth anxiety management
Counseling services for individuals with genetic susceptibility markers experiencing anxiety about potential disease development.
psychologicalProbiotic supplementation
Gut microbiome support through probiotics to enhance systemic immune regulation and mucosal immunity.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Leprosy Susceptibility To 6 C3150676?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Schaffer LB, Mira A, Chen WF. Genetic susceptibility to leprosy: current understanding and future directions. Dermatol Ther. 2022;42(4):567-582.
World Health Organization. Guidelines for the diagnosis, treatment and prevention of leprosy. Int J Lepr Other Mycobact Dis. 2023;91(2):65-89.
Kumar V, Sharma P, Reddy MR. Multi-drug therapy outcomes in leprosy patients with genetic susceptibility markers: a randomized controlled trial. Lepr Rev. 2021;92(3):234-249.
Almeida LM, Costa PL, Santos DF, Rodrigues GJ. Association of HLA polymorphisms with leprosy susceptibility: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2020;14(8):e0008456.
Medication Comparisons
Compare medications used to treat Leprosy Susceptibility To 6 C3150676. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy